Quick Answer
Alto Neuroscience, Inc. reported Operating Income Loss of -$66.36 million for the year ending 2025.
- Alto Neuroscience, Inc. showed an increase of +3.3% in Operating Income Loss from 2024 to 2025.
- This data is from Alto Neuroscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$7.20 million | Q2 2023: -$9.13 million | Q3 2023: -$9.72 million | Q1 2024: -$14.39 million | Q2 2024: -$18.34 million | Q3 2024: -$18.89 million | Q1 2025: -$15.68 million | Q2 2025: -$18.68 million | Q3 2025: -$14.95 million.
- Over the full 3 years of available data (2023 to 2025), Alto Neuroscience, Inc.'s Operating Income Loss has declined by 75.5%.
- Historical annual values: Fiscal year 2025: -$66.36 million | Fiscal year 2024: -$68.61 million | Fiscal year 2023: -$37.81 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: